Microbiota Composition in Diverticular Disease: Implications for Therapy
Abstract
:1. Introduction
2. Profiling the GM in Diverticulosis
3. Profiling the GM in SUDD
4. Profiling the GM in AD
5. Rationalization of the GM Changes in DD Compared with Chronic Intestinal Inflammation
5.1. Inflammation
5.2. Age
5.3. Diet
5.4. Comorbidities and Polypharmacy
6. How Microbiota Changes Impact DD Treatment: The Role of Probiotics
6.1. Probiotics in SUDD
6.2. Probiotics in AUD
7. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Tursi, A.; Scarpignato, C.; Strate, L.L.; Lanas, A.; Kruis, W.; Lahat, A.; Danese, S. Colonic diverticular disease. Nat. Rev. Dis. Prim. 2020, 6, 20. [Google Scholar] [CrossRef]
- Tursi, A.; Elisei, W.; Franceschi, M.; Picchio, M.; Di Mario, F.; Brandimarte, G. The prevalence of symptomatic uncomplicated diverticular disease could be lower than expected: A single-center colonoscopy-based cohort study. Eur. J. Gastroenterol. Hepatol. 2021, 33 (Suppl. S1), e478–e483. [Google Scholar] [CrossRef]
- Tursi, A.; Franceschi, M.; Elisei, W.; Picchio, M.; Mario, F.D.; Brandimarte, G. The natural history of symptomatic uncomplicated diverticular disease: A long-term follow-up study. Ann. Gastroenterol. 2021, 34, 208–213. [Google Scholar] [CrossRef]
- Shahedi, K.; Fuller, G.; Bolus, R.; Cohen, E.; Vu, M.; Shah, R.; Agarwal, N.; Kaneshiro, M.; Atia, M.; Sheen, V.; et al. Long-term risk of acute diverticulitis among patients with incidental diverticulosis found during colonoscopy. Clin. Gastroenterol. Hepatol. 2013, 11, 1609–1613. [Google Scholar] [CrossRef] [Green Version]
- Giorgetti, G.; Brandimarte, G.; Fabiocchi, F.; Ricci, S.; Flamini, P.; Sandri, G.; Trotta, M.C.; Elisei, W.; Penna, A.; Lecca, P.G.; et al. Interactions between Innate Immunity, Microbiota, and Probiotics. J. Immunol. Res. 2015, 2015, 501361. [Google Scholar] [CrossRef] [PubMed]
- Ni, J.; Wu, G.D.; Albenberg, L.; Tomov, V.T. Gut microbiota and IBD: Causation or correlation? Nat. Rev. Gastroenterol. Hepatol. 2017, 14, 573–584. [Google Scholar] [CrossRef] [Green Version]
- Jones, R.B.; Fodor, A.A.; Peery, A.F.; Tsilimigras, M.C.B.; Winglee, K.; McCoy, A.; Sioda, M.; Sandler, R.S.; Keku, T.O. An Aberrant Microbiota is not Strongly Associated with Incidental Colonic Diverticulosis. Sci. Rep. 2018, 8, 4951. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- van Rossen, T.M.; Ooijevaar, R.E.; Kuyvenhoven, J.P.; Eck, A.; Bril, H.; Buijsman, R.; Boermeester, M.A.; Stockmann, H.B.A.C.; de Korte, N.; Budding, A.E. Microbiota composition and mucosal immunity in patients with asymptomatic diverticulosis and controls. PLoS ONE 2021, 16, e0256657. [Google Scholar] [CrossRef]
- Ponziani, F.R.; Scaldaferri, F.; Petito, V.; Paroni Sterbini, F.; Pecere, S.; Lopetuso, L.R.; Palladini, A.; Gerardi, V.; Masucci, L.; Pompili, M.; et al. The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin. Dig. Dis. 2016, 34, 269–278. [Google Scholar] [CrossRef]
- Tursi, A.; Mastromarino, P.; Capobianco, D.; Elisei, W.; Miccheli, A.; Capuani, G.; Tomassini, A.; Campagna, G.; Picchio, M.; Giorgetti, G.; et al. Assessment of Fecal Microbiota and Fecal Metabolome in Symptomatic Uncomplicated Diverticular Disease of the Colon. J. Clin. Gastroenterol. 2016, 50 (Suppl. S1), S9–S12. [Google Scholar] [CrossRef] [PubMed]
- Barbara, G.; Scaioli, E.; Barbaro, M.R.; Biagi, E.; Laghi, L.; Cremon, C.; Marasco, G.; Colecchia, A.; Picone, G.; Salfi, N.; et al. Gut microbiota, metabolome and immune signatures in patients with uncomplicated diverticular disease. Gut 2017, 66, 1252–1261. [Google Scholar] [CrossRef]
- Kvasnovsky, C.L.; Leong, L.E.X.; Choo, J.M.; Abell, G.C.J.; Papagrigoriadis, S.; Bruce, K.D.; Rogers, G.B. Clinical and symptom scores are significantly correlated with fecal microbiota features in patients with symptomatic uncomplicated diverticular disease: A pilot study. Eur. J. Gastroenterol. Hepatol. 2018, 30, 107–112. [Google Scholar] [CrossRef]
- Lopetuso, L.R.; Petito, V.; Graziani, C.; Schiavoni, E.; Paroni Sterbini, F.; Poscia, A.; Gaetani, E.; Franceschi, F.; Cammarota, G.; Sanguinetti, M.; et al. Gut Microbiota in Health, Diverticular Disease, Irritable Bowel Syndrome, and Inflammatory Bowel Diseases: Time for Microbial Marker of Gastrointestinal Disorders. Dig. Dis. 2018, 36, 56–65. [Google Scholar] [CrossRef]
- Linninge, C.; Roth, B.; Erlanson-Albertsson, C.; Molin, G.; Toth, E.; Ohlsson, B. Abundance of Enterobacteriaceae in the colon mucosa in diverticular disease. World J. Gastrointest. Pathophysiol. 2018, 9, 18–27. [Google Scholar] [CrossRef]
- Laghi, L.; Mastromarino, P.; Elisei, W.; Capobianco, D.; Zhu, C.L.; Picchio, M.; Giorgetti, G.; Brandimarte, G.; Tursi, A. Impact of treatments on fecal microbiota and fecal metabolome in symptomatic uncomplicated diverticular disease of the colon: A pilot study. J. Biol. Regul. Homeost. Agents 2018, 32, 1421–1432. [Google Scholar] [PubMed]
- Machiels, K.; Joossens, M.; Sabino, J.; De Preter, V.; Arijs, I.; Eeckhaut, V.; Ballet, V.; Claes, K.; Van Immerseel, F.; Verbeke, K.; et al. A decrease of the butyrate producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 2014, 63, 1275–1283. [Google Scholar] [CrossRef] [PubMed]
- Ponziani, F.R.; Scaldaferri, F.; De Siena, M.; Mangiola, F.; Matteo, M.V.; Pecere, S.; Petito, V.; Sterbini, F.P.; Lopetuso, L.R.; Masucci, L.; et al. Increased Faecalibacterium abundance is associated with clinical improvement in patients receiving rifaximin treatment. Benef. Microbes 2020, 11, 519–525. [Google Scholar] [CrossRef]
- Tursi, A.; Mastromarino, P.; Capobianco, D.; Elisei, W.; Campagna, G.; Picchio, M.; Giorgetti, G.; Fabiocchi, F.; Brandimarte, G. Faecalibacterium prausnitzii is not decreased in symptomatic uncomplicated diverticular disease of the colon. Biosci. Microbiota Food Health 2022, 2022–2046. [Google Scholar] [CrossRef]
- Gueimonde, M.; Ouwehand, A.; Huhtinen, H.; Salminen, E.; Salminen, S. Qualitative and quantitative analyses of the bifidobacterial microbiota in the colonic mucosa of patients with colorectal cancer, diverticulitis, and inflammatory bowel disease. World J. Gastroenterol. 2007, 13, 3985–3989. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Daniels, L.; Budding, A.E.; de Korte, N.; Eck, A.; Bogaards, J.A.; Stockmann, H.B.; Consten, E.C.; Savelkoul, P.H.; Boermeester, M.A. Fecal microbiome analysis as a diagnostic test for diverticulitis. Eur. J. Clin. Microbiol. Infect. Dis. 2014, 33, 1927–1936. [Google Scholar] [CrossRef] [PubMed]
- Schieffer, K.M.; Sabey, K.; Wright, J.R.; Toole, D.R.; Drucker, R.; Tokarev, V.; Harris, L.R.; Deiling, S.; Eshelman, M.A.; Hegarty, J.P.; et al. The Microbial Ecosystem Distinguishes Chronically Diseased Tissue from Adjacent Tissue in the Sigmoid Colon of Chronic, Recurrent Diverticulitis Patients. Sci. Rep. 2017, 7, 8467. [Google Scholar] [CrossRef] [PubMed]
- O’Grady, M.J.; Turner, G.A.; Sulit, A.; Frizelle, F.A.; Purcell, R. Distinct changes in the colonic microbiome associated with acute diverticulitis. Color. Dis. 2022, 1–11. [Google Scholar] [CrossRef]
- Hayashi, A.; Sato, T.; Kamada, N.; Mikami, Y.; Matsuoka, K.; Hisamatsu, T.; Hibi, T.; Roers, A.; Yagita, H.; Ohteki, T.; et al. A single strain of Clostridium butyricum induces intestinal IL-10-producing macrophages to suppress acute experimental colitis in mice. Cell Host Microbe 2013, 13, 711–722. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Atarashi, K.; Tanoue, T.; Oshima, K.; Suda, W.; Nagano, Y.; Nishikawa, H.; Fukuda, S.; Saito, T.; Narushima, S.; Hase, K.; et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 2013, 500, 232–236. [Google Scholar] [CrossRef]
- Rodriguez-Nogales, A.; Algieri, F.; Garrido-Mesa, J.; Vezza, T.; Utrilla, M.P.; Chueca, N.; Garcia, F.; Olivares, M.; Rodríguez-Cabezas, M.E.; Gálvez, J. Differential intestinal anti-inflammatory effects of Lactobacillus fermentum and Lactobacillus salivarius in DSS mouse colitis: Impact of microRNAs expression and microbiota composition. Mol. Nutr. Food Res. 2017, 61, 1700144. [Google Scholar] [CrossRef]
- Knox, N.C.; Forbes, J.D.; Peterson, C.L.; Van Domselaar, G.; Bernstein, C.N. The Gut Microbiome in Inflammatory Bowel Disease: Lessons Learned From Other Immune-Mediated Inflammatory Diseases. Am. J. Gastroenterol. 2019, 114, 1051–1070. [Google Scholar] [CrossRef] [PubMed]
- Lopez-Siles, M.; Enrich-Capo, N.; Aldeguer, X.; Sabat-Mir, M.; Duncan, S.H.; Garcia-Gil, L.J.; Martinez-Medina, M. Alterations in the Abundance and Co-occurrence of Akkermansia muciniphila and Faecalibacterium prausnitzii in the Colonic Mucosa of Inflammatory Bowel Disease Subjects. Front. Cell. Infect. Microbiol. 2018, 8, 281. [Google Scholar] [CrossRef]
- Belzer, C.; de Vos, W.M. Microbes inside—From diversity to function: The case of Akkermansia. ISME J. 2012, 6, 1449–1458. [Google Scholar] [CrossRef]
- Alam, A.; Leoni, G.; Quiros, M.; Wu, H.; Desai, C.; Nishio, H.; Jones, R.M.; Nusrat, A.; Neish, A.S. The microenvironment of injured murine gut elicits a local pro-restitutive microbiota. Nat. Microbiol. 2016, 1, 15021. [Google Scholar] [CrossRef] [Green Version]
- Derrien, M.; Vaughan, E.E.; Plugge, C.M.; de Vos, W.M. Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int. J. Syst. Evol. Microbiol. 2004, 54, 1469–1476. [Google Scholar] [CrossRef]
- Van Passel, M.W.; Kant, R.; Zoetendal, E.G.; Plugge, C.M.; Derrien, M.; Malfatti, S.A.; Chain, P.S.; Woyke, T.; Palva, A.; de Vos, W.M.; et al. The genome of Akkermansia muciniphila, a dedicated intestinal mucin degrader, and its use in exploring intestinal metagenomes. PLoS ONE 2011, 6, e16876. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Everard, A.; Belzer, C.; Geurts, L.; Ouwerkerk, J.P.; Druart, C.; Bindels, L.B.; Guiot, Y.; Derrien, M.; Muccioli, G.G.; Delzenne, N.M.; et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc. Natl. Acad. Sci. USA 2013, 110, 9066–9071. [Google Scholar] [CrossRef] [Green Version]
- Macchione, I.G.; Lopetuso, L.R.; Ianiro, G.; Napoli, M.; Gibiino, G.; Rizzatti, G.; Petito, V.; Gasbarrini, A.; Scaldaferri, F. Akkermansia muciniphila: Key player in metabolic and gastrointestinal disorders. Eur. Rev. Med. Pharmacol. Sci. 2019, 23, 8075–8083. [Google Scholar] [PubMed]
- Lopetuso, L.R.; Quagliariello, A.; Schiavoni, M.; Petito, V.; Russo, A.; Reddel, S.; del Chierico, F.; Ianiro, G.; Scaldaferri, F.; Neri, M.; et al. Towards a disease-associated common trait of gut microbiota dysbiosis: The pivotal role of Akkermansia muciniphila. Dig. Liver Dis. 2020, 52, 1002–1010. [Google Scholar] [CrossRef] [PubMed]
- Hall, A.B.; Yassour, M.; Sauk, J.; Garner, A.; Jiang, X.; Arthur, T.; Lagoudas, G.K.; Vatanen, T.; Fornelos, N.; Wilson, R.; et al. A novel Ruminococcus gnavus clade enriched in inflammatory bowel disease patients. Genome Med. 2017, 9, 103. [Google Scholar] [CrossRef] [PubMed]
- Tursi, A.; Elisei, W.; Brandimarte, G.; Giorgetti, G.M.; Inchingolo, C.D.; Nenna, R.; Picchio, M.; Giorgio, F.; Ierardi, E. Musosal tumor necrosis factor α in diverticular disease of the colon is overexpressed with disease severity. Color. Dis. 2012, 14, e258–e263. [Google Scholar] [CrossRef]
- Humes, D.J.; Simpson, J.; Smith, J.; Sutton, P.; Zaitoun, A.; Bush, D.; Bennett, A.; Scholefield, J.H.; Spiller, R.C. Visceral hypersensitivity in symptomatic diverticular disease and the role of neuropeptides and low grade inflammation. Neurogastroenterol. Motil. 2012, 24, 318-e163. [Google Scholar] [CrossRef] [PubMed]
- Tursi, A.; Elisei, W.; Inchingolo, C.D.; Nenna, R.; Picchio, M.; Ierardi, E.; Brandimarte, G. Chronic diverticulitis and Crohn’s disease share the same expression of basic fibroblastic growth factor, syndecan 1 and tumor necrosis factor-α. J. Clin. Pathol. 2014, 67, 844–846. [Google Scholar] [CrossRef] [PubMed]
- Connelly, T.M.; Choi, C.S.; Berg, A.S.; Harris, L., 3rd.; Coble, J.; Koltun, W.A. Diverticulitis and Crohn’s disease have distinct but overlapping tumor necrosis superfamily 15 haplotypes. J. Surg. Res. 2017, 214, 262–269. [Google Scholar] [CrossRef]
- Dai, L.; King, D.W.; Perera, D.S.; Lubowski, D.Z.; Burcher, E.; Liu, L. Inverse expression of prostaglandin E2-related enzymes highlights differences between diverticulitis and inflammatory bowel disease. Dig. Dis. Sci. 2015, 60, 1236–1246. [Google Scholar] [CrossRef]
- Li, M.C.; He, S.H. IL-10 and its related cytokines for treatment of inflammatory bowel disease. World J. Gastroenterol. 2004, 10, 620–625. [Google Scholar] [CrossRef] [PubMed]
- Tursi, A.; Mastromarino, P.; Capobianco, D.; Elisei, W.; Picchio, M.; Brandimarte, G. No changes in Interleukin-10 expression in symptomatic uncomplicated diverticular disease of the colon. J. Gastrointest. Liver Dis. 2018, 27, 476–477. [Google Scholar] [CrossRef] [PubMed]
- Turco, F.; Andreozzi, P.; Palumbo, I.; Zito, F.P.; Cargiolli, M.; Fiore, W.; Gennarelli, N.; De Palma, G.D.; Sarnelli, G.; Cuomo, R. Bacterial stimuli activate nitric oxide colonic mucosal production in diverticular disease. Protective effects of L. casei DG® (Lactobacillus paracasei CNCM I-1572). United Eur. Gastroenterol. J. 2017, 5, 715–724. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- O’Toole, P.W.; Jeffery, I.B. Gut microbiota and aging. Science 2015, 350, 1214–1215. [Google Scholar] [CrossRef]
- Bischoff, S.C. Microbiota and aging. Curr. Opin. Clin. Nutr. Metab. Care 2016, 19, 26–30. [Google Scholar] [CrossRef]
- Ottman, N.; Smidt, H.; de Vos, W.M.; Belzer, C. The function of our microbiota: Who is out there and what do they do? Front. Cell. Infect. Microbiol. 2012, 2, 104. [Google Scholar] [CrossRef] [Green Version]
- Biagi, E.; Nylund, L.; Candela, M.; Ostan, R.; Bucci, L.; Pini, E.; Nikkïla, J.; Monti, D.; Satokari, R.; Franceschi, C.; et al. Through ageing, and beyond: Gut microbiota and inflammatory status in seniors and centenarians. PLoS ONE 2010, 5, e10667. [Google Scholar] [CrossRef]
- Heinritz, S.N.; Weiss, E.; Eklund, M.; Aumiller, T.; Heyer, C.M.; Messner, S.; Rings, A.; Louis, S.; Bischoff, S.C.; Mosenthin, R. Impact of a high-fat or high-fiber diet on intestinal microbiota and metabolic markers in a pig model. Nutrients 2016, 8, 317. [Google Scholar] [CrossRef]
- Dominianni, C.; Sinha, R.; Goedert, J.J.; Pei, Z.; Yang, L.; Hayes, R.B.; Ahn, J. Sex, body mass index, and dietary fiber intake influence the human gut microbiome. PLoS ONE 2015, 10, e0124599. [Google Scholar] [CrossRef] [Green Version]
- Chen, H.M.; Yu, Y.N.; Wang, J.L.; Lin, Y.W.; Kong, X.; Yang, C.Q.; Yang, L.; Liu, Z.J.; Yuan, Y.Z.; Liu, F.; et al. Decreased dietary fiber intake and structural alteration of gut microbiota in patients with advanced colorectal carcinoma. Am. J. Clin. Nutr. 2013, 97, 1044–1052. [Google Scholar] [CrossRef]
- Macia, L.; Tan, J.; Vieira, A.T.; Leach, K.; Stanley, D.; Luong, S.; Maruya, M.; McLenzie, I.; Hijkata, A.; Wong, C.; et al. Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome. Nat. Commun. 2015, 6, 6734. [Google Scholar] [CrossRef] [Green Version]
- Zhu, Y.; Shi, X.; Lin, X.; Ye, K.; Xu, X.; Li, C.; Zhou, G. Beef, chicken, and soy proteins in diets induce different gut microbiota and metabolites in rats. Front. Microbiol. 2017, 8, 1395. [Google Scholar] [CrossRef] [Green Version]
- Engen, P.A.; Green, S.J.; Voigt, R.M.; Forsyth, C.B.; Keshavarzian, A. The gastrointestinal microbiome: Alcohol effects on the composition of intestinal microbiota. Alcohol Res. 2015, 37, 223–236. [Google Scholar]
- Mentella, M.C.; Scaldaferri, F.; Pizzoferrato, M.; Gasbarrini, A.; Miggiano, G.A.D. Nutrition, IBD and Gut Microbiota: A Review. Nutrients 2020, 12, 944. [Google Scholar] [CrossRef] [Green Version]
- Sugihara, K.; Kamada, N. Diet-Microbiota Interactions in Inflammatory Bowel Disease. Nutrients 2021, 13, 1533. [Google Scholar] [CrossRef]
- Ananthakrishnan, A.N.; Khalili, H.; Song, M.; Higuchi, L.M.; Richter, J.M.; Chan, A.T. Zinc intake and risk of Crohn’s disease and ulcerative colitis: A prospective cohort study. Int. J. Epidemiol. 2015, 44, 1995–2005. [Google Scholar] [CrossRef]
- Ananthakrishnan, A.N.; Khalili, H.; Konijeti, G.G.; Higuchi, L.M.; de Silva, P.; Korzenik, J.R.; Fuchs, C.S.; Willett, W.C.; Richter, J.M.; Chan, A.T. A prospective study of long-term intake of dietary fiber and risk of Crohn’s disease and ulcerative colitis. Gastroenterology 2013, 145, 970–977. [Google Scholar] [CrossRef] [Green Version]
- Tursi, A.; Brandimarte, G.; Di Mario, F.; Elisei, W.; Picchio, M.; Allegretta, L.; Annunziata, M.L.; Bafutto, M.; Bassotti, G.; Bianco, M.A.; et al. An international, multicentre, prospective cohort study is the prognostic performance of the ‘DICA’ endoscopic classification and the ‘CODA’ score in predicting clinical outcomes of diverticular disease. Gut 2022, 71, 1350–1358. [Google Scholar] [CrossRef]
- Ticinesi, A.; Milani, C.; Lauretani, F.; Nouvenne, A.; Mancabelli, L.; Lugli, G.A.; Turroni, F.; Duranti, S.; Mangifesta, M.; Viappiani, A.; et al. Gut microbiota composition is associated with polypharmacy in elderly hospitalized patients. Sci. Rep. 2017, 7, 11102. [Google Scholar] [CrossRef] [Green Version]
- Jackson, M.A.; Verdi, S.; Maxan, M.E.; Shin, C.M.; Zierer, J.; Bowyer, R.C.E.; Martin, T.; Williams, F.M.K.; Menni, C.; Bell, J.T.; et al. Gut microbiota associations with common diseases and prescription medications in a population-based cohort. Nat. Commun. 2018, 9, 2655. [Google Scholar] [CrossRef] [Green Version]
- Zhuang, X.; Tian, Z.; Feng, R.; Li, M.; Li, T.; Zhou, G.; Qiu, Y.; Chen, B.; He, Y.; Chen, M.; et al. Fecal Microbiota Alterations Associated With Clinical and Endoscopic Response to Infliximab Therapy in Crohn’s Disease. Inflamm. Bowel Dis. 2020, 26, 1636–1647. [Google Scholar] [CrossRef] [PubMed]
- Chen, L.; Lu, Z.; Kang, D.; Feng, Z.; Li, G.; Sun, M.; Liu, Z.; Wu, W.; Fang, L. Distinct alterations of fecal microbiota refer to the efficacy of adalimumab in Crohn’s disease. Front. Pharmacol. 2022, 13, 913720. [Google Scholar] [CrossRef] [PubMed]
- Ribaldone, D.G.; Caviglia, G.P.; Abdulle, A.; Pellicano, R.; Ditto, M.C.; Morino, M.; Fusaro, E.; Saracco, G.M.; Bugianesi, E.; Astegiano, M. Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn’s Disease. J. Clin. Med. 2019, 8, 1646. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Radhakrishnan, S.T.; Alexander, J.L.; Mullish, B.H.; Gallagher, K.I.; Powell, N.; Hicks, L.C.; Hart, A.L.; Li, J.V.; Marchesi, J.R.; Williams, H.R.T. Systematic review: The association between the gut microbiota and medical therapies in inflammatory bowel disease. Aliment. Pharmacol. Ther. 2022, 55, 26–48. [Google Scholar] [CrossRef] [PubMed]
- Montalban-Arques, A.; De Schryver, P.; Bossier, P.; Gorkiewicz, G.; Mulero, V.; Gatlin, D.M., 3rd.; Galindo-Villegas, J. Selective Manipulation of the Gut Microbiota Improves Immune Status in Vertebrates. Front. Immunol. 2015, 6, 512. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Scarpignato, C.; Bertelé, A.; Tursi, A. Probiotics for the Treatment of Symptomatic Uncomplicated Diverticular Disease: Rationale and Current Evidence. J. Clin. Gastroenterol. 2016, 50 (Suppl. S1), S70–S73. [Google Scholar] [CrossRef]
- Rondanelli, M.; Faliva, M.A.; Perna, S.; Giacosa, A.; Peroni, G.; Castellazzi, A.M. Using probiotics in clinical practice: Where are we now? A review of existing meta-analyses. Gut Microbes 2017, 8, 521–543. [Google Scholar] [CrossRef] [Green Version]
- Ticinesi, A.; Nouvenne, A.; Corrente, V.; Tana, C.; Di Mario, F.; Meschi, T. Diverticular Disease: A Gut Microbiota Perspective. J. Gastrointest. Liver Dis. 2019, 28, 327–337. [Google Scholar] [CrossRef]
- Kvasnovsky, C.L.; Bjarnason, I.; Donaldson, A.N.; Sherwood, R.A.; Papagrigoriadis, S. A randomized double-blind placebo-controlled trial of a multi-strain probiotic in treatment of symptomatic uncomplicated diverticular disease. Inflammopharmacology 2017, 25, 499–509. [Google Scholar] [CrossRef]
- Tursi, A.; Brandimarte, G.; Elisei, W.; Picchio, M.; Forti, G.; Pianese, G.; Rodino, S.; D’Amico, T.; Sacca, N.; Portincasa, P.; et al. Randomised clinical trial: Mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease: A double-blind, randomised, placebo-controlled study. Aliment. Pharmacol. Ther. 2013, 38, 741–751. [Google Scholar] [CrossRef]
- Bretto, E.; D’Amico, F.; Fiore, W.; Tursi, A.; Danese, S. Lactobacillus paracasei CNCM I 1572: A Promising Candidate for Management of Colonic Diverticular Disease. J. Clin. Med. 2022, 11, 1916. [Google Scholar] [CrossRef] [PubMed]
- Petruzziello, C.; Migneco, A.; Cardone, S.; Covino, M.; Saviano, A.; Franceschi, F.; Ojetti, V. Supplementation with Lactobacillus reuteri ATCC PTA 4659 in patients affected by acute uncomplicated diverticulitis: A randomized double-blind placebo controlled trial. Int. J. Color. Dis. 2019, 34, 1087–1109. [Google Scholar] [CrossRef] [PubMed]
- Ojetti, V.; Saviano, A.; Brigida, M.; Petruzziello, C.; Caronna, M.; Gayani, G.; Franceschi, F. Randomized control trial on the efficacy of Limosilactobacillus reuteri ATCC PTA 4659 in reducing inflammatory markers in acute uncomplicated diverticulitis. Eur. J. Gastroenterol. Hepatol. 2022, 34, 496–502. [Google Scholar] [CrossRef] [PubMed]
Authors (Years) [Reference] | Study Design | Overall Study Population | Sampling Methods | Detection Methods | Microbiome Association with Diverticulosis | Treatment | Main Findings |
---|---|---|---|---|---|---|---|
Jones (2018) | Case-control | 535 consecutive patients (226 with diverticulosis and 309 controls). | Mucosal sampling during colonoscopy. | PCR metagenomics | Proteobacteria and Comamondaceae | None | No significant differences between cases and controls except for a slight reduction in Proteobacteria and Comamondaceae species among cases. |
van Rossen (2021) | Case-control | 43 consecutive patients (19 with diverticulosis and 24 controls). | Mucosal sampling during colonoscopy. | 16S rRNA | None | None | No significant differences between cases and controls. |
Authors (Years) [Reference] | Study Design | Overall Study Population | Sampling Methods | Detection Methods | Microbiome Association with Diverticular Disease | Treatment | Main Findings |
---|---|---|---|---|---|---|---|
Ponziani (2016) | Case-control | 20 consecutive patients (4 SUDD, 4 IBS, 4 CD, 4 UC, 4 HE) | Stool | 16S rRNA | Roseburia and Colinsella | Rifaximin | Significant increase in Roseburia and Colinsella (which decreased after rifaximin treatment) in SUDD). Significant reduction in Lactobacilli (which increased after rifaximin treatment) in SUDD. |
Tursi (2016) | Case-control | 44 consecutive patients (only women: 15 SUDD, 13 diverticulosis, 16 controls) | Stool | Real-time PCR | A. muciniphila | None | Significant increase in Akkermansia in SUDD compared with controls. |
Barbara (2017) | Case-control | 38 consecutive patients (8 SUDD, 14 diverticulosis, 16 controls) | Mucosal sampling during colonoscopy | 16S rRNA | Clostridium Cluster IX, Fusobacterium, and Lactobacillaceae | None | Significant decrease in Clostridium Cluster IX, Fusobacterium, and Lactobacillaceae in SUDD; A. muciniphila reduced in the diverticular district compared with the colonic district without diverticula. |
Lopetuso (2018) | Case-Control | 28 consecutive patients (4 SUDD, 3 IBS, 10 CD, 8 UC, 8 controls) | Stool | 16S rRNA | Bacteroides fragilis, Colinsella, and Riminococcaceae | None | Ruminococcaceae increased in SUDD, with depletion of Colinsella and Bacterioidetes fragilis. |
Linninge (2018) | Case-control | 51 consecutive patients (16 SUDD and 24 controls) | Mucosal sampling during colonoscopy | PCR-based profiling | Enterobacteriaceae | None | Increased abundance of Enterobacteriaceae in SUDD compared with controls. |
Kvasnovsky (2018) | Cohort | 30 consecutive SUDD patients (15 PD-SUDD and 15 NPD-SUDD) | Stool | 16S rRNA | Pseudobutyrivibrio Bifidobacterium, Christensenellaceae, Mollicutes RF9, Bacteroides, Faecalibacterium, and Ruminococcus | None | Bacteroides, Faecalibacterium, and Ruminococcus increased in all SUDD patients.
|
Laghi (2018) | Cohort | 13 consecutive SUDD patients (15 PD-SUDD and 15 NPD-SUDD) | Stool | Real-time PCR | Akkermansia muciniphila | Probiotic mixture, rifaximin, mesalazine, fibers | Significant decrease in Akkermansia under treatment, parallel with symptom improvement.
|
Ponziani (2020) | Case-control | 25 consecutive patients (7 SUDD, 8 IBS, 5 CD, 5 UC) | Stool | 16S rRNA | Faecalibacterium, Ruminococcus, and Roseburia | Rifaximin | Significant increase in Fecalibacterium and a significant decrease in Roseburia and Ruminococcus in patients responding to rifaximin. |
Tursi (2022) | Case-control | 44 consecutive patients (only women: 15 SUDD, 13 diverticulosis, 16 controls) | Stool | Real-time PCR | F. prausnitzii | None | Slight increase (not significant) in F. prausnitzii in SUDD compared with controls. |
Authors (Years) [Reference] | Study Design | Overall Study Population | Sampling Methods | Detection Methods | Microbiome Association with Acute Diverticulitis | Treatment | Main Findings |
---|---|---|---|---|---|---|---|
Gueimonde (2007) | Cohort | 34 patients (21 CRC, 9 AD, 4 IBD) | Mucosal biopsy during surgery | 16S rRNA microbial profiling | Bifidobacterium longum | Surgery | B. longum significantly increased in AD vs. CRC and IBD. |
Daniels (2014) | Case-control | 56 patients (31 AUD and 25 controls) | Rectal swab | PCR based | Enterobacteriaceae | None | Enterobacteriaceae abundant in AD. |
Schieffer (2017) | Cohort | Nine patients (resected diverticulitis) | Mucosal biopsy on surgical specimen | 16S rRNA | Microbacteriaceae | Surgery | The mucosal microbiota associated with disease overexpressed Microbacteriaceae compared with the microbiota related to adjacent tissue. |
O’Grady (2022) | Case-control | 82 patients (44 AUD, 21 ACD, 27 controls) | Rectal swab | 16S rRNA | Lachnospiraceae, Ruminococcus, and Faecalibacterium Fusobacteria, Prevotella, and Paraprevotella | None | Lachnospiraceae, Ruminococcus, and Faecalibacterium decreased in AD; Fusobacteria, Prevotella, and Paraprevotella increased in AD; Prevotella, Fusicatenibacter, and Faecalibacterium more abundant in ACD than in AUD. |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Tursi, A.; Papa, V.; Lopetuso, L.R.; Settanni, C.R.; Gasbarrini, A.; Papa, A. Microbiota Composition in Diverticular Disease: Implications for Therapy. Int. J. Mol. Sci. 2022, 23, 14799. https://doi.org/10.3390/ijms232314799
Tursi A, Papa V, Lopetuso LR, Settanni CR, Gasbarrini A, Papa A. Microbiota Composition in Diverticular Disease: Implications for Therapy. International Journal of Molecular Sciences. 2022; 23(23):14799. https://doi.org/10.3390/ijms232314799
Chicago/Turabian StyleTursi, Antonio, Valerio Papa, Loris Riccardo Lopetuso, Carlo Romano Settanni, Antonio Gasbarrini, and Alfredo Papa. 2022. "Microbiota Composition in Diverticular Disease: Implications for Therapy" International Journal of Molecular Sciences 23, no. 23: 14799. https://doi.org/10.3390/ijms232314799